KOREA PHARMA Co., Ltd. (KOSDAQ:032300)
South Korea
· Delayed Price · Currency is KRW 14,880
-170 (-1.13%)
Last updated: Mar 25, 2025
KOREA PHARMA Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Operating Revenue | 81,277 | 83,240 | 81,029 | 79,577 | 71,510 | Upgrade
|
| Other Revenue | - | -0 | -0 | - | - | Upgrade
|
| Revenue | 81,277 | 83,240 | 81,029 | 79,577 | 71,510 | Upgrade
|
| Revenue Growth (YoY) | -2.36% | 2.73% | 1.83% | 11.28% | 8.13% | Upgrade
|
| Cost of Revenue | 46,127 | 46,337 | 45,614 | 43,679 | 37,365 | Upgrade
|
| Gross Profit | 35,150 | 36,903 | 35,415 | 35,898 | 34,145 | Upgrade
|
| Selling, General & Admin | 25,031 | 25,938 | 24,983 | 24,502 | 21,802 | Upgrade
|
| Research & Development | 2,053 | 2,313 | 2,452 | 4,893 | 6,221 | Upgrade
|
| Other Operating Expenses | 530.99 | 561.44 | 622.52 | 611.61 | 542.74 | Upgrade
|
| Operating Expenses | 29,064 | 31,063 | 29,228 | 30,883 | 29,541 | Upgrade
|
| Operating Income | 6,086 | 5,840 | 6,187 | 5,014 | 4,604 | Upgrade
|
| Interest Expense | -2,880 | -3,738 | -3,867 | -908.17 | -435.67 | Upgrade
|
| Interest & Investment Income | 1,397 | 510.74 | 211.94 | 57.42 | 17.28 | Upgrade
|
| Earnings From Equity Investments | 1,644 | -1,724 | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 162.72 | -39.62 | 26.82 | 18.41 | -43.66 | Upgrade
|
| Other Non Operating Income (Expenses) | -2,590 | -139.55 | -4,378 | 1,019 | -382.76 | Upgrade
|
| EBT Excluding Unusual Items | 3,820 | 710.03 | -1,819 | 5,201 | 3,759 | Upgrade
|
| Gain (Loss) on Sale of Investments | 364.1 | 1,910 | -42.2 | 1.93 | 9.11 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.14 | 0.32 | 81.9 | 5.29 | - | Upgrade
|
| Asset Writedown | -279.24 | -606.42 | - | - | - | Upgrade
|
| Pretax Income | 3,906 | 2,014 | -1,780 | 5,208 | 3,768 | Upgrade
|
| Income Tax Expense | 114.21 | 1,931 | -660.63 | -1,160 | 608.75 | Upgrade
|
| Net Income | 3,792 | 83.76 | -1,119 | 6,368 | 3,159 | Upgrade
|
| Net Income to Common | 3,792 | 83.76 | -1,119 | 6,368 | 3,159 | Upgrade
|
| Net Income Growth | 4426.69% | - | - | 101.59% | -42.85% | Upgrade
|
| Shares Outstanding (Basic) | 11 | 10 | 11 | 11 | 10 | Upgrade
|
| Shares Outstanding (Diluted) | 11 | 10 | 12 | 11 | 10 | Upgrade
|
| Shares Change (YoY) | 4.06% | -13.85% | 10.50% | 12.80% | 10.95% | Upgrade
|
| EPS (Basic) | 348.00 | 8.00 | -102.60 | 584.00 | 324.00 | Upgrade
|
| EPS (Diluted) | 348.00 | 8.00 | -102.60 | 579.00 | 324.00 | Upgrade
|
| EPS Growth | 4250.00% | - | - | 78.70% | -48.49% | Upgrade
|
| Free Cash Flow | 4,797 | 3,288 | 5,815 | 4,640 | -2,848 | Upgrade
|
| Free Cash Flow Per Share | 440.24 | 314.06 | 478.44 | 421.87 | -292.05 | Upgrade
|
| Gross Margin | 43.25% | 44.33% | 43.71% | 45.11% | 47.75% | Upgrade
|
| Operating Margin | 7.49% | 7.02% | 7.64% | 6.30% | 6.44% | Upgrade
|
| Profit Margin | 4.67% | 0.10% | -1.38% | 8.00% | 4.42% | Upgrade
|
| Free Cash Flow Margin | 5.90% | 3.95% | 7.18% | 5.83% | -3.98% | Upgrade
|
| EBITDA | 8,883 | 8,653 | 8,567 | 7,391 | 6,824 | Upgrade
|
| EBITDA Margin | 10.93% | 10.40% | 10.57% | 9.29% | 9.54% | Upgrade
|
| D&A For EBITDA | 2,797 | 2,813 | 2,380 | 2,377 | 2,221 | Upgrade
|
| EBIT | 6,086 | 5,840 | 6,187 | 5,014 | 4,604 | Upgrade
|
| EBIT Margin | 7.49% | 7.02% | 7.64% | 6.30% | 6.44% | Upgrade
|
| Effective Tax Rate | 2.92% | 95.84% | - | - | 16.16% | Upgrade
|
| Advertising Expenses | 1,230 | 1,569 | 1,224 | 858.02 | 588.21 | Upgrade
|
Updated Mar 1, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.